NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $905,656 | +6787.6% | 1,520,578 | +6552.0% | 0.00% | – |
| Q2 2023 | $13,149 | -99.5% | 22,859 | -94.8% | 0.00% | -100.0% |
| Q1 2022 | $2,392,000 | -61.7% | 443,800 | -4.0% | 0.01% | -64.0% |
| Q4 2021 | $6,246,000 | -34.0% | 462,300 | -12.3% | 0.02% | -40.5% |
| Q3 2021 | $9,467,000 | +3281.1% | 527,100 | +3262.0% | 0.04% | +2000.0% |
| Q1 2020 | $280,000 | -81.5% | 15,678 | -81.1% | 0.00% | -77.8% |
| Q3 2019 | $1,512,000 | -35.6% | 83,000 | +275.6% | 0.01% | -10.0% |
| Q1 2018 | $2,348,000 | +1748.8% | 22,100 | +140.2% | 0.01% | +900.0% |
| Q1 2016 | $127,000 | -56.9% | 9,200 | -47.4% | 0.00% | -50.0% |
| Q4 2015 | $295,000 | -80.4% | 17,500 | -87.3% | 0.00% | -83.3% |
| Q3 2015 | $1,507,000 | – | 137,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |